SRC and neoplasm: We next tested the efficacy of an improved pan-SRC inhibitor (SI-2) [25], AZD, or the combination in a patient-derived xenograft (PDX) expressing Y537S ERα (WHIM 20 [11]) for tumor reduction (Fig. 3a).